Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck
Florence Duffaud(Aix-Marseille Université), P. Fumoleau(Institut Curie), Joël S. Bloch(Sorbonne Université), P. Chollet(Centre Jean Perrin), Didier Lacombe(Centre Hospitalier Universitaire de Bordeaux), B. Barón, J. B. Vermorken, Markus Borner(University of Bern), Christian Dittrich(Leibniz Institute for Agricultural Engineering and Bioeconomy), F. Rolland(Institut de Cancérologie de l'Ouest), M. Degardin(Centre Hospitalier Universitaire de Nantes)
Cited by 42
Related Papers
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
|The Lancet|2011|1.1k
Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutières syndrome and mimic congenital viral brain infection
|Nature Genetics|2006|673
Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study
|Journal of Clinical Oncology|2013|418
Evaluation of DNA Methylation Episignatures for Diagnosis and Phenotype Correlations in 42 Mendelian Neurodevelopmental Disorders
|The American Journal of Human Genetics|2020|334